NRSN (NeuroSense Therapeutics) Debt-to-Equity: -0.11 (As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.73
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Debt-to-Equity?

NeuroSense Therapeutics NRSN +1.19% 29 Debt-to-Equity is -0.11 as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, NeuroSense Therapeutics ranks worse than 103519.57% on this metric.

NeuroSense Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.10 Mil. NeuroSense Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.07 Mil. NeuroSense Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-1.56 Mil. NeuroSense Therapeutics's debt to equity for the quarter that ended in Dec. 2025 was -0.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NeuroSense Therapeutics's Debt-to-Equity or its related term are showing as below:

NRSN' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.11   Med: -0.03   Max: 0.04
Current: -0.11

During the past 7 years, the highest Debt-to-Equity Ratio of NeuroSense Therapeutics was 0.04. The lowest was -0.11. And the median was -0.03.

NRSN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs NRSN: -0.11

NeuroSense Therapeutics  (NAS:NRSN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NeuroSense Therapeutics Debt-to-Equity Related Terms

NeuroSense Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Debt-to-Equity Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial 0.00 0.04 -0.08 0.03 -0.11

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.02 0.03 0.00 -0.11

NRSN vs SER, PVCT, IGC: Debt-to-Equity Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Debt-to-Equity falls into.


NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NeuroSense Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.098 + 0.072) / -1.56
=-0.11

NeuroSense Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.098 + 0.072) / -1.56
=-0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.11 mean?
NeuroSense Therapeutics (NRSN) has a Debt-to-Equity of -0.11 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NeuroSense Therapeutics and its competitors. According to the industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 966 companies in the Biotechnology industry.
Is NeuroSense Therapeutics' Debt-to-Equity too high?
NeuroSense Therapeutics' current Debt-to-Equity is -0.11. Based on the distribution chart, NeuroSense Therapeutics ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Debt-to-Equity compare to SER and PVCT?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #999999 out of 966 companies for Debt-to-Equity. This places NeuroSense Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NeuroSense Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroSense Therapeutics's current Debt-to-Equity is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Debt-to-Equity of -0.11. The current Debt-to-Equity is -0.11. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Debt-to-Equity is -0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price